In this study, we enrolled 123 patients with NSCLC who were resistant to first-line EGFR-TKIs and analyzed the clinical efficacy of PD-1/PD-L1 inhibitors by counting PFS, OS, ORR and DCR of all patients to explore the efficacy of ICIs as second-line treatment in patients with EGFR-TKIs-resistant advanced NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.